Form 13-F position report

VISTAGEN THERAPEUTICS INC COM

Reported by MORGAN STANLEY

VTGN CUSIP 92840H400 Manager CIK 0000895421

Reported 5,319 shares, down 547 (9.3%) from the prior quarter.

Reported value -21.6%; share count -9.3% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2024
Shares 5,319 Quarter-end amount reported
Reported value $16,010 Fair value at quarter end
Consecutive quarters held 6 Through Q3 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-06-30 6396
2023-09-30 13414
2023-12-31 100610
2024-03-31 113304
2024-06-30 20414
2024-09-30 16010
2024-12-31 50421
2025-03-31 128213
2025-06-30 24294
2025-09-30 97746
2025-12-31 8378
2026-03-31 0
2026-06-30 67
2026-09-30 41

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for VISTAGEN THERAPEUTICS INC COM held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 132 -166 (-55.7%) < 0.01% $41 2026-11-13
Q2 2026 New 298 +298 (0.0%) < 0.01% $67 2026-08-13
Q1 2026 Reduced 0 -12,658 (-100.0%) 0 $0 2026-05-15
Q4 2025 Reduced 12,658 -14,876 (-54.0%) < 0.01% $8,378 2026-02-13
Q3 2025 Added 27,534 +15,387 (126.7%) < 0.01% $97,746 2025-11-14
Q2 2025 Reduced 12,147 -39,138 (-76.3%) < 0.01% $24,294 2025-08-15
Q1 2025 Added 51,285 +34,193 (200.1%) < 0.01% $128,213 2025-05-15
Q4 2024 Added 17,092 +11,773 (221.3%) < 0.01% $50,421 2025-02-14
Q3 2024 Reduced 5,319 -547 (-9.3%) < 0.01% $16,010 2024-11-14
Q2 2024 Reduced 5,866 -15,593 (-72.7%) < 0.01% $20,414 2024-08-14
Q1 2024 Added 21,459 +1,885 (9.6%) < 0.01% $113,304 2024-05-15
Q4 2023 Added 19,574 +17,014 (664.6%) < 0.01% $100,610 2024-02-13
Q3 2023 Reduced 2,560 -860 (-25.1%) < 0.01% $13,414 2023-11-15
Q2 2023 New 3,420 +3,420 (0.0%) < 0.01% $6,396 2023-08-14

Who else reported the position

51 managers reported VISTAGEN THERAPEUTICS INC COM for Q3 2024.

Managers reporting VISTAGEN THERAPEUTICS INC COM in Q3 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
TCG Crossover Management LLC New 2,676,580 +2,676,580 0.68% $8,056,505 1 qtr
BVF INC IL Unchanged 2,000,000 0 0.18% $6,020,000 4 qtrs
VANGUARD GROUP INC Unchanged 1,793,166 0 < 0.01% $5,397,430 6 qtrs
STEMPOINT CAPITAL LP Reduced 1,846,792 -1,790 1.47% $4,900,565 4 qtrs
COMMODORE CAPITAL LP Unchanged 1,575,000 0 0.3% $4,740,750 5 qtrs
Nantahala Capital Management LLC Unchanged 1,517,696 0 0.23% $4,568,265 4 qtrs
SPHERA FUNDS MANAGEMENT LTD Unchanged 808,550 0 0.39% $2,433,736 5 qtrs
GREAT POINT PARTNERS LLC Reduced 674,075 -855,263 0.6% $2,028,966 4 qtrs
BlackRock Inc New 412,129 +412,129 < 0.01% $1,240,509 1 qtr
CITADEL ADVISORS LLC Reduced 321,885 -307,760 < 0.01% $968,874 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2024
Filed
November 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
4,902
Shared
0
None
417

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.